Innoviva (INVA) Net Income towards Common Stockholders (2010 - 2026)
Innoviva posted quarterly Net Income towards Common Stockholders of $186.6 million for Q1 2026, up 500.44% year-on-year from $31.1 million in Q1 2025, and up 1449.66% on a QoQ basis from -$13.8 million in Q4 2025.
Innoviva (INVA) has 17 years of Net Income towards Common Stockholders data on file, last reported at $186.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 500.44% year-over-year to $186.6 million; the trailing twelve-month figure through Mar 2026 stood at $326.3 million (up 460.2% YoY), and the FY2025 full-year result was $271.4 million, up 1060.07% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at $186.6 million, up from -$13.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $265.5 million in Q3 2022 and bottomed at -$46.6 million in Q1 2025.
- The 5-year median for Net Income towards Common Stockholders is $1.3 million (2023), against an average of $38.6 million.
- The widest annual swing landed in 2024, when Net Income towards Common Stockholders sank 2809.77%; it then soared 7312.78% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$10.3 million in 2022, then surged by 36.31% to -$6.6 million in 2023, then plunged by 60.22% to -$10.5 million in 2024, then tumbled by 31.16% to -$13.8 million in 2025, then surged by 1449.66% to $186.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $186.6 million (Q1 2026), -$13.8 million (Q4 2025), and $89.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 186.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186.56 Mn |
| Dec 31, 2025 | -13.82 Mn |
| Sep 30, 2025 | 89.92 Mn |
| Jun 30, 2025 | 63.69 Mn |
| Mar 31, 2025 | -46.59 Mn |
| Dec 31, 2024 | -10.54 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | -34.69 Mn |
| Mar 31, 2024 | 36.52 Mn |
| Dec 31, 2023 | -6.58 Mn |
| Sep 30, 2023 | 82.05 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 34.87 Mn |
| Dec 31, 2022 | -10.33 Mn |
| Sep 30, 2022 | 265.52 Mn |
| Jun 30, 2022 | 939,000.00 |
| Mar 31, 2022 | 15.77 Mn |
| Dec 31, 2021 | -6.05 Mn |
| Sep 30, 2021 | 72.44 Mn |
| Jun 30, 2021 | 88.95 Mn |
| Mar 31, 2021 | 94.12 Mn |
| Dec 31, 2020 | 53.90 Mn |
| Sep 30, 2020 | 28.22 Mn |
| Jun 30, 2020 | 76.84 Mn |
| Mar 31, 2020 | 65.44 Mn |
| Dec 31, 2019 | 45.95 Mn |
| Sep 30, 2019 | 39.81 Mn |
| Jun 30, 2019 | 37.74 Mn |
| Mar 31, 2019 | 33.79 Mn |
| Dec 31, 2018 | 263.76 Mn |
| Sep 30, 2018 | 47.09 Mn |
| Jun 30, 2018 | 54.63 Mn |
| Mar 31, 2018 | 29.58 Mn |
| Dec 31, 2017 | 58.39 Mn |
| Sep 30, 2017 | 23.77 Mn |
| Jun 30, 2017 | 35.15 Mn |
| Mar 31, 2017 | 16.85 Mn |
| Dec 31, 2016 | 25.88 Mn |
| Sep 30, 2016 | 15.03 Mn |
| Jun 30, 2016 | 14.60 Mn |
| Mar 31, 2016 | 4.44 Mn |
| Dec 31, 2015 | 4.30 Mn |
| Sep 30, 2015 | -4.58 Mn |
| Jun 30, 2015 | -7.81 Mn |
| Mar 31, 2015 | -10.67 Mn |
| Dec 31, 2014 | -15.93 Mn |
| Sep 30, 2014 | -21.27 Mn |
| Jun 30, 2014 | -63.56 Mn |
| Mar 31, 2014 | -67.70 Mn |
| Dec 31, 2013 | -49.93 Mn |
| Sep 30, 2013 | -46.99 Mn |
| Jun 30, 2013 | -36.43 Mn |
| Mar 31, 2013 | -37.36 Mn |
| Dec 31, 2012 | -31.32 Mn |
| Sep 30, 2012 | -34.69 Mn |
| Jun 30, 2012 | -37.12 Mn |
| Mar 31, 2012 | 84.59 Mn |
| Dec 31, 2011 | -37.01 Mn |
| Sep 30, 2011 | -30.63 Mn |
| Jun 30, 2011 | -25.05 Mn |
| Mar 31, 2011 | -22.67 Mn |
| Dec 31, 2010 | -19.30 Mn |
| Sep 30, 2010 | -21.22 Mn |
| Jun 30, 2010 | -20.81 Mn |